FTSE MIB
34.825,01 -573,81 (-1,62%) Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
38.946,93 -122,75 (-0,31%) Petrolio
79,29 -0,51 (-0,64%) Bitcoin EUR
65.484,92 +4.123,81 (+6,72%)
CRBP May 2024 35.000 put
| Chiusura precedente | 2,0000 |
| Aperto | 1,1500 |
| Denaro | 0,0000 |
| Lettera | 1,0000 |
| Prezzo d'esercizio | 35,00 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 1,1500 - 2,3700 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 44 |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
